New rules went into effect during 2018 on the Hong Kong stock exchange allowing companies that did not have a product on the market or generate revenue to list on the exchange.

The Biotechnology Industry Organization released a report titled: Emerging Therapeutic Company Investment and Deal Trends. BIO Industry Analysis says more than 90 percent of the biopharma industry is composed of small, emerging companies. According to BIO President Jim Greenwood and E. Cartier Esham, Ph.D., executive VP of BIO’s Emerging Companies Section, it is important for the trade association to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be affecting the ability to maintain a robust pipeline of innovative medicines.

The biotechnology arena’s financing total for 2015 reached unprecedented heights for the second straight year, according to EY’s 29th annual Beyond borders report. Biotech companies raised nearly $71 billion in 2015, well ahead of the previous record of $56 billion totaled during 2014.

The biotechnology industry hauled in $2.3 billion worth of venture capital investments during the second quarter of this year—a 32% increase over the prior quarter, according to the newest MoneyTree […]